2 breakthrough ASX healthcare shares

Australia has helped shape modern medicine in many ways. These 2 ASX healthcare shares are breakthrough companies with strong momentum.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian medical sector has been one of the great drivers of innovation in global health for decades. For example, Australians created the electronic pacemaker. In addition, together with Alexander Fleming, we helped pioneer the life saving application of penicillin. We also developed the world's first vaccine to prevent cervical cancer. Consequently, it should be no surprise that we have a range of breakthrough healthcare shares on the ASX today.

I believe the following ASX healthcare shares have, firstly, pioneered solutions for new or unmet challenges and, secondly, started to gain some momentum. 

Defeating sepsis

Sepsis is a life-threatening, inflammatory response to infection that has spread in the body. Consequently, any infection has the potential to cause sepsis. The following figures may shock you, they shocked me.

A study published in The Lancet medical journal in 2018 revealed there were 11 million sepsis-related deaths worldwide in 2017 alone. The study, which included 195 countries, highlighted the fact that sepsis accounted for 19.7% of all deaths globally. Kind of puts things into perspective doesn't it? 

Enter Recce Pharmaceuticals Ltd (ASX: RCE). This ASX healthcare share is developing a new class of synthetic antibiotics. They are designed to deal with the new form of antibiotic-resistant superbugs. As such, they continue to be effective, even with repeated use. 

The company's primary focus has been to develop a treatment for sepsis. Its lead candidate, RECCE® 327, has received awards labelling it for 'fast track designation'. This allows global regulators to expedite the review and approvals process. Furthermore, it grants the product 10 years of market exclusivity post approval.

On Thursday, following a 2-day pause, Recce shares began trading again after announcing two of its products had been selected as part of a CSIRO study for antiviral treatments to manage COVID-19. Correspondingly, the Recce share price rocketed up by 54.14% yesterday.

Healing broken bones

Osteopore Ltd (ASX: OSX) is an ASX healthcare share that has patented a world first technology in the production of 3D-printed, bioresorbable implants. These implants are used in conjunction with surgical procedures to facilitate bone healing. They do this by providing a lattice or framework between the two ends of a break for the bone to grow back on. Once the bone has healed, the material is absorbed into the body.

Alternatives to Osteopore include bone grafts and permanent implants, i.e. plates and pins. There are, however, competitors to Osteopore in the substitute bone graft space. Nevertheless, the company's competitive advantage lies in its 3D printing technology, for which it holds a number of patents. Moreover, this technology is precise and allows for customisation of shape and geometry.

The current bone graft substitute market is worth around US$4 billion, whereas sales of permanent implants are estimated at over US$100 billion annually. Most of which is in the United States.

As at February 2020, the company's products had been used to successfully treat around 30,000 patients, predominantly in the Asia Pacific region. On 2 July, Osteopore announced it has signed a distribution agreement with a United States company. This opens up significant opportunities for it to capitalise on this highly lucrative market. The Osteopore share price rocketed more than 270% to a new all-time high of $1.49 following the announcement. Shares have since fallen back and are currently trading at 58 cents. 

Foolish takeaway

These are just two of the many pioneering, healthcare shares available on the ASX. I believe they offer proven technologies and limited requirement for regulatory approval (or considerable expertise in how to navigate the regulatory system, at the very least). I expect both of these healthcare shares to do well over the medium term. Having said that, being fairly newly listed, small caps, there is likely still a lot of bumpy road between now and a 10 times increase in the current share price.

Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »